TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06459908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot Glove Hand Training
Description: Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Hand Rehabilitation Exercises
Description: Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hand Rehabilitation Exercises
Description: Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
Study: NCT05278247

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
Study: NCT05435092

Intervention type: RADIATION
Intervention: 3D-reconstruction CT
Description: Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
Study: NCT05082220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection using ultrasound and fluoroscopic guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection using ultrasound and fluoroscopic guidance
Study: NCT06246162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-MIT combination regimen
Description: Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed.
Study: NCT04200937

Intervention type: DEVICE
Intervention: Tactra Malleable
Description: The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.

Intervention type: DEVICE
Intervention: Spectra™ Concealable Penile Prothesis
Description: The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.

Intervention type: DEVICE
Intervention: AMS Ambicor™ Inflatable Penile Prosthesis
Description: The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.

Intervention type: DEVICE
Intervention: AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump
Description: The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).

Intervention type: DEVICE
Intervention: AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump
Description: The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
Study: NCT06149806

Intervention type: DRUG
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
Study: NCT05510791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun Sport Drink
Description: Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
Study: NCT05626452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Education
Description: Education for participants regarding PrEP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider training
Description: Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Optimization
Description: EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Navigation
Description: Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Audit and Feedback
Description: Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
Study: NCT04775927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: premarital education
Study: NCT04782245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
Study: NCT05894538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT05126264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: morning and afternoon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: morning, afternoon and night
Study: NCT05979636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novamin containing toothpaste
Description: children's teeth will be brushed using Novamin containing toothpaste.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride containing toothpaste
Description: children's teeth will be brushed using Fluoride containing toothpaste.
Study: NCT04829474

Intervention type: OTHER
Intervention: Survey
Description: It is a survey that the patient and doctor must complete.
Study: NCT04194736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan.
Study: NCT04720274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyopathy (EMG) Shorts
Description: Participants will be asked to complete physical activities while wearing EMG shorts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyopathy (EMG) Shorts
Description: Participants will be asked to complete physical activities while wearing EMG shorts
Study: NCT05212012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
Description: Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
Study: NCT05928897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Sintilimab
Description: Disitamab Vedotin combined with Sintilimab
Study: NCT06511219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary segmental distalization
Description: maxillary segmental distalization using skeletal anchored digitally printed appliances

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary segmental distalization
Description: maxillary segmental distalization using skeletal anchored digitally printed appliances
Study: NCT05813795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecnoglutide Low Dosage
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecnoglutide Medium Dosage
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecnoglutide High Dosage
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection with matched volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection with matched volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection with matched volume
Study: NCT05838885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH
Description: YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH
Description: YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH
Description: rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH
Description: rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Study: NCT05319145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 1) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: General recommendations (written and videos) will be offered.
Study: NCT06574789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing of IV ganciclovir
Description: IV ganciclovir at standard dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Personalised dosing of IV ganciclovir
Description: IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app
Study: NCT06577337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M5542
Description: Participants will receive single ascending dose of M5542 subcutaneously on Day 1 in Part A. Participants will receive loading dose of M5542 followed by maintenance doses in Part B.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5542 in Part A and Part B.
Study: NCT05849103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Control Targets
Description: This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Control Targets
Description: This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Control Targets
Description: This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Control Targets
Description: This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertension Management
Description: This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertension Management
Description: This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertension Management
Description: This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertension Management
Description: This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
Study: NCT05982392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg will be given 60 minutes before start of procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Naproxen sodium 550mg will be given 60 minutes before start of procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 60 minutes before start of procedure.
Study: NCT04406727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: UB-421 in combination with their ARV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral (ARV)
Description: Antiretroviral (ARV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV)
Description: Antiretroviral (ARV)
Study: NCT05319522

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute Exercise
Description: Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute Exercise
Description: Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
Study: NCT04761289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise and Functional Rehabilitation Program
Description: 1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Exercise and Functional Rehabilitation Program
Description: 1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment.
Study: NCT05184140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node detection
Description: Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis.
Study: NCT05124964

Intervention type: OTHER
Intervention: PedsQL 4.0 Scale
Description: The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.

Intervention type: OTHER
Intervention: Short Form-36
Description: Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.

Intervention type: OTHER
Intervention: Chinese Wechsler Intelligence Scale for Children
Description: The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
Study: NCT05294445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of atrial fibrillation (AF)
Description: Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
Study: NCT04835909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern board and card games group
Description: Modern board and card games group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper and pencil tasks group
Description: Paper and pencil tasks group
Study: NCT05450341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over right frontal target
Description: Low frequency (1 Hz) rTMS over right inferior frontal gyrus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS over right temporal target
Description: Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
Study: NCT06087666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FICare
Description: The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
Study: NCT04841902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life Style Intervention Manual (With Exercise Under Supervision)
Description: Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Advice
Description: General advice to stay healthy and active

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life Style Intervention Manual (Home Based)
Description: Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.